Trevi Therapeutics CFO files Form 3, no holdings
Trevi Therapeutics, Inc. executive David C. Hastings, the company’s Chief Financial Officer, filed an initial Form 3 ownership report as of 01/08/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Trevi Therapeutics, Inc. executive David C. Hastings, the company’s Chief Financial Officer, filed an initial Form 3 ownership report as of 01/08/2026.
The filing indicates that he has no securities beneficially owned in Trevi Therapeutics, with both the non-derivative and derivative securities tables showing no holdings. A power of attorney (Exhibit 24.1) authorizes attorney-in-fact Christopher Galletta to sign the form on his behalf.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Trevi Therapeutics (TRVI) disclose in this Form 3 filing?
Who is the reporting person in Trevi Therapeutics (TRVI) Form 3?
What is the event date for the Trevi Therapeutics (TRVI) Form 3?
Does the Trevi Therapeutics (TRVI) CFO own any non-derivative or derivative securities?
Who signed the Trevi Therapeutics (TRVI) Form 3 on behalf of the CFO?
Is this Trevi Therapeutics (TRVI) Form 3 filed by one or multiple reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.